Bayer Supervisory Board Member Buys Shares Under Board Purchase Commitment

Bayer ( (DE:BAYN) ) has issued an announcement.

Bayer disclosed a managers’ transaction under EU market abuse rules, reporting that supervisory board member Kimberly Mathisen purchased Bayer shares on March 6, 2026 via the Xetra trading platform. The acquisition, totaling €56,550 at a price of €37.70 per share, was made in connection with the Supervisory Board members’ commitment to buy Bayer AG stock, signaling continued alignment of board members’ interests with those of shareholders.

The reported share purchase underscores Bayer’s adherence to regulatory transparency requirements on insider dealings and may be read by investors as a modest vote of confidence from the company’s oversight body. While financially small in scale relative to Bayer’s market value, such transactions can influence market perception of governance quality and board engagement, particularly at a time when investors closely scrutinize insider activity in large European blue chips.

The most recent analyst rating on (DE:BAYN) stock is a Buy with a EUR50.00 price target. To see the full list of analyst forecasts on Bayer stock, see the DE:BAYN Stock Forecast page.

More about Bayer

Bayer Aktiengesellschaft is a German life sciences group with core businesses in pharmaceuticals, consumer health and crop science. The company’s shares are listed on major regulated markets in Germany, including Frankfurt and other regional exchanges, and it is a constituent of key European equity benchmarks.

Average Trading Volume: 3,879,105

Technical Sentiment Signal: Hold

Current Market Cap: €38.93B

See more insights into BAYN stock on TipRanks’ Stock Analysis page.